TYRPHOSTIN A23

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H6N2O2
Molecular Weight	186.1668
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C(C=C(C#N)C#N)C=C1O

InChI

InChIKey=VTJXFTPMFYAJJU-UHFFFAOYSA-N

InChI=1S/C10H6N2O2/c11-5-8(6-12)3-7-1-2-9(13)10(14)4-7/h1-4,13-14H

HIDE SMILES / InChI

Molecular Formula	C10H6N2O2
Molecular Weight	186.1668
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8260363 | https://www.ncbi.nlm.nih.gov/pubmed/21887406 | https://www.ncbi.nlm.nih.gov/pubmed/3263702 | https://www.ncbi.nlm.nih.gov/pubmed/27894844

Tyrphostin A23 belongs to a novel class of low molecular weight proteins that inhibit protein tyrosine kinase and block the EGF-dependent autophosphorylation of the receptor. It has been considered as potential anti-cancer drug. It inhibits pancreatic cancer cell growth in vitro. Inhibition of EGF receptor by tyrphostin A23 was associated with a significantly increased proportion of apoptotic cells in human prostate cancer DU145 cell culture.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Epidermal growth factor receptor 46 Target ID: CHEMBL2363049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3263702	Inhibitor 8297	10.0 µM [Ki]
PDGFR (rabbit) 1 Target ID: PDGFR (rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7892601	Inhibitor 8297	25.0 µM [IC50]
p210 (BCR-ABL1) 1 Target ID: p210 (BCR-ABL1) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7892601	Inhibitor 8297	75.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Prostate cancer 178 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21887406	Primary		Basic research	Unknown Approved Use Unknown
Pancreatic cancer 97 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8260363	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.	1989 Oct	2552117

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Both lactate production and glucose consumption were increased in the primary astrocytes by the presence of Tyrphostin A23 (T23) in a concentration-dependent manner. Exposure to 100 uM T23 increased already within the initial 15 min of incubation the extracellular lactate concentration significantly from 0.37±0.01 (control, absence of T23) to 0.91±0.30 uM/mg.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:16:59 GMT 2023` Edited by `admin` on `Sat Dec 16 02:16:59 GMT 2023`
Record UNII	RV0GCD31OJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TYRPHOSTIN A23

Common Name

English

AG 18

Code

English

RG-50810

Code

English

AG-18

Code

English

(3,4-DIHYDROXYBENZYLIDENE)MALONONITRILE

Systematic Name

English

TYRPHOSTIN 23

Common Name

English

((3,4-DIHYDROXYPHENYL)METHYLENE)-PROPENEDINITRILE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1757